These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16163370)

  • 21. Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction.
    Hirsch IH; Smith RL; Chancellor MB; Bagley DH; Carsello J; Staas WE
    Paraplegia; 1994 Oct; 32(10):661-4. PubMed ID: 7831071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostaglandin E1 in the therapy of erectile deficiency.
    Beretta G; Zanollo A; Ascani L; Re B
    Acta Eur Fertil; 1989; 20(5):305-8. PubMed ID: 2636808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Slow injection of prostaglandin E1 decreases associated penile pain.
    Gheorghiu D; Godschalk M; Gheorghiu S; Mulligan T
    Urology; 1996 Jun; 47(6):903-4. PubMed ID: 8677586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relation between intracavernosal dose of prostaglandin Pge 1 and mean duration of erection in men with different underlying causes of erectile dysfunction.
    Bratus D; Hlebic G; Hajdinjak T
    Croat Med J; 2007 Feb; 48(1):76-80. PubMed ID: 17309142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prostaglandin treatment in neurological patients with erectile dysfunction].
    Conejero Sugrañes J; Muñoz Villellas A; Sarrias Lorenz F; Ramírez Garceran L
    Arch Esp Urol; 2002; 55(1):63-8. PubMed ID: 11957754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intracavernous auto-injection of prostaglandin E1 for diagnosis and treatment of erectile dysfunction].
    Arielly J; Weinberg D; Eliraz A; Adam M; el-Hanani BI; Eisenkraft S
    Harefuah; 1994 Apr; 126(7):369-73, 426. PubMed ID: 8200581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Erectile response to intracavernous injection of linsidomine in 38 impotent patients. Comparison with prostaglandin E1].
    Lemaire A; Buvat J
    Prog Urol; 1998 Jun; 8(3):388-91. PubMed ID: 9689672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracavernous injection therapy for male erectile dysfunction.
    Fallon B
    Urol Clin North Am; 1995 Nov; 22(4):833-45. PubMed ID: 7483132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of a needle-free high-pressure injection system with needle-tipped injection of intracavernosal alprostadil for erectile dysfunction.
    Harding LM; Adeniyi A; Everson R; Barker S; Ralph DJ; Baranowski AP
    Int J Impot Res; 2002 Dec; 14(6):498-501. PubMed ID: 12494285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracavernous pharmacotherapy: comparison of Moxisylyte and prostaglandin E1.
    Buvat J; Lemaire A; Herbaut-Buvat M
    Int J Impot Res; 1996 Jun; 8(2):41-6. PubMed ID: 8858388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intracavernous injection of lipo prostaglandin E1 for the diagnosis of impotence: a comparative study with prostaglandin E1-CD].
    Yajima M; Baba K; Minagawa N; Kohno S; Haraguchi C; Iwamoto T; Osada T
    Hinyokika Kiyo; 1993 Mar; 39(3):289-92. PubMed ID: 8506803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tadalafil and modifications in peak systolic velocity (Doppler spectrum dynamic analysis) in the cavernosal arteries of patients with type 2 diabetes after continuous tadalafil treatment.
    La Vignera S; Calogero AE; Cannizzaro MA; Condorelli R; Noto Z; Vicari E
    Minerva Endocrinol; 2006 Dec; 31(4):251-61. PubMed ID: 17213792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection and short-term infusion of prostaglandin E1 in patients with erectile dysfunction.
    Cawello W; Schweer H; Dietrich B; Seyberth HW; Albrecht D; Fox A; Hohmuth H
    J Urol; 1997 Oct; 158(4):1403-7. PubMed ID: 9302131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous temperature measurements in men with penile prostheses: a comparison study.
    Fogarty JD; Bleustein CB; Hafron JM; Melman A
    Int J Impot Res; 2005; 17(6):506-9. PubMed ID: 15889119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostaglandin E1 as treatment for erectile failure in elderly men.
    Godschalk MF; Chen J; Katz PG; Mulligan T
    J Am Geriatr Soc; 1994 Dec; 42(12):1263-5. PubMed ID: 7983289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Retrospective study on the incidence and cause of drop-out during intracavernous pharmaco-prosthesis therapy].
    Giammusso B; Motta M
    Arch Ital Urol Androl; 2002 Mar; 74(1):27-31. PubMed ID: 12053447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostaglandin E1 long-term self-injection programme for treatment of erectile dysfunction--a follow-up of at least 5 years.
    Hauck EW; Altinkilic BM; Schroeder-Printzen I; Rudnick J; Weidner W
    Andrologia; 1999; 31 Suppl 1():99-103. PubMed ID: 10643527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life in patients using self-administered intracavernous injections of prostaglandin E1 for erectile dysfunction.
    Gheorghiu S; Godschalk M; Gentili A; Mulligan T
    J Urol; 1996 Jul; 156(1):80-1. PubMed ID: 8648844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy of a new formulation of prostaglandin E1 as treatment for erectile failure.
    Godschalk M; Gheorghiu D; Chen J; Katz PG; Mulligan T
    J Urol; 1996 Mar; 155(3):915-7. PubMed ID: 8583606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracavernous prostaglandin E1 in erectile dysfunction.
    Linet OI; Neff LL
    Clin Investig; 1994 Jan; 72(2):139-49. PubMed ID: 8186662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.